Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04458935 · ClinicalTrials.gov registry record
Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma
A clinical trial of Von Hippel-Lindau Disease and Retinal Hemangioblastoma, sponsored by National Eye Institute (NEI).
- Active
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT04458935 is a study of Von Hippel-Lindau Disease and Retinal Hemangioblastoma that is active but no longer recruiting, run by National Eye Institute (NEI). The registered enrollment target is 25 participants, below the 2,239-participant average among 5 other Von Hippel-Lindau Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04458935, a study of Von Hippel-Lindau Disease and Retinal Hemangioblastoma, is active but no longer recruiting, sponsored by National Eye Institute (NEI).
- ACTIVE NOT RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Retinal hemangioblastoma (RH) is a tumor. It grows from the retina in the eye. It can threaten a person s vision. Trans-scleral cryotherapy is used to destroy the tumors and minimize the long-term risks of vision loss. RH is a rare condition, often occurring in people with von Hippel-Lindau disease. There are no clinical trials to study how well the treatment works. Researchers want to study the medical records of people with RH who were treated at the NIH eye clinic to learn more. Objective: To analyze clinical data collected over a 20-year span to study consecutive cases of RH managed with trans-scleral cryotherapy at the NIH. Eligibility: People who took part in NIH natural history protocols for which cryotherapy of RH was performed as a standard care measure. Design: Researchers will collect and study data from participants medical charts. Participants will not be contacted because no new data is needed. Researchers were granted a waiver of informed consent for use of these medical records. To protect patient privacy, participants will be assigned an ID number. Their data will be entered into a spreadsheet in a coded fashion. The key to this code will be kept in a secure file. No patient identifying information will be used in the analysis or the publication....
Conditions Studied
Study Locations (1)
Maryland
- National Eye Institute (NEI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-07-02 |
| Est. Completion | 2026-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04458935
The ClinicalTrials.gov registry entry for NCT04458935 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,239-participant average among 5 other Von Hippel-Lindau Disease trials with a reported enrollment target (99% lower). The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Von Hippel-Lindau Disease appearing as the primary indexed condition, and to 0 interventions.
NCT04458935 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04458935 about?
NCT04458935 is a clinical study titled "Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma". Background: Retinal hemangioblastoma (RH) is a tumor. It grows from the retina in the eye. It can threaten a person s vision. Trans-scleral cryotherapy is used to destroy the tumors and minimize the long-term risks of vision loss. RH is a rare condition, often occurring in people with von Hippel-Li...
What is the current status of trial NCT04458935?
This trial is currently active not recruiting. The enrollment target is 25 participants. The study started on 2020-07-02. Estimated completion is 2026-06-30.
What conditions does trial NCT04458935 study?
This clinical trial studies the following conditions: Von Hippel-Lindau Disease, Retinal Hemangioblastoma.
Who is sponsoring clinical trial NCT04458935?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04458935 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Hippel-Lindau Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
RECRUITING · Phase 2
-
MyVHL: Patient Natural History Study
RECRUITING
-
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
RECRUITING · Phase 2
-
Data Collection Protocol for Patients With Von Hippel Lindau Disease
RECRUITING
-
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.